🍪 CompoundTalk uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsClinical Trials & ResearchEfinopegdutide — MASH-focused GCG/GLP-1 from Merck/Hanmi Page 2

Efinopegdutide — MASH-focused GCG/GLP-1 from Merck/Hanmi

MASHdoc_SA Thu, May 21, 2026 at 7:54 AM 8 replies 347 viewsPage 2 of 2
KevinCompounds
VIP Member
5,432
18,234
Dec 2023
Nevada
May 21, 2026 at 12:43 PM#6
Dr.ObesityLA said:
Liver enzyme update related to liver and MASH: I had mildly elevated ALT/AST at baseline (likely NAFLD).

Liver ultrasound comparison for liver and MASH: my hepatologist ordered serial ultrasounds to track NAFLD regression.

Baseline: "Moderate hepatic steatosis, liver span 17.2cm, echogenic texture consistent with fat infiltration"
Month 8: "Mild steatosis, liver span 15.8cm, improved echogenicity"
Month 14: "Minimal to no steatosis, normal liver span 14.5cm, normal echotexture"

My liver literally shrank and de-fattened. The ultrasound tech said she's seen this pattern increasingly in GLP-1 patients and it's remarkable how consistently the fatty liver resolves.

6 9jennifer_SEA, tyler_CSCS, VanRx_Mike and 3 others
Reply Quote Save Share Report
BethLabQueen
Senior Member
1,234
5,678
May 2024
Virginia
Online
May 21, 2026 at 2:36 PM#7
MASHdoc_SA said:
ALT was mildly raised at baseline, normalised at month five, and I now have no idea whether anything happened to the fibrosis that actually matters.

Liver imaging follow-up for liver and MASH: FibroScan at baseline showed CAP score 326 dB/m (moderate steatosis) and stiffness 10.8 kPa (possible fibrosis). Diagnosed with NAFLD.

After 12 months: CAP dropped to 239 dB/m (minimal steatosis) and stiffness normalized to 6.199999999999999 kPa. Hepatologist says the liver is essentially healing itself as the metabolic stress resolves.

GLP-1 agonists may become first-line NASH therapy. The Phase 3 data on semaglutide for NASH is very promising.

7 10Dr.PulmRoch, maya_sedona, stefan_berlin and 4 others
Reply Quote Save Share Report
andrew_nyc
Member
534
2,345
Apr 2024
New York, NY
May 21, 2026 at 4:29 PM#8
KevinCompounds said:
Liver ultrasound comparison for liver and MASH: my hepatologist ordered serial ultrasounds to track NAFLD regression.

Coming at KevinCompounds’s question from a different direction. Order of operations matters more than any single choice here: establish a baseline, change one thing, wait long enough for it to express itself, then measure again under the same conditions.

8 11PharmD_Rodriguez, julia.endo, JessicaM_2024 and 5 others
Reply Quote Save Share Report

PeptideMeter — Independent Peptide Analytics

Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.

View Results
tampaLisa73
Member
312
1,456
Oct 2024
Tampa, FL
May 21, 2026 at 6:22 PM#9

Following on from claudia_zurich — and this may be the naive question:

How would you tell the difference between that and the alternative explanation?

9 12mike.trainer_LA, sarah_nash92, FitDadDave and 6 others
Reply Quote Save Share Report
MASHdoc_SA
Member
456
2,345
Aug 2024
San Antonio, TX
May 22, 2026 at 3:22 AM#10

OP back with an update, since a thread like this is useless without one.

For the archive: it took about six weeks rather than the two I expected, and the difference between those two numbers was the whole of my problem.

33 8kate.chem, DataDave, Dr.GutHealth and 30 others
Reply Quote Save Share Report

Similar Threads

FLOW trial: semaglutide renal outcomes — NEJM publication review14 replies
SELECT trial: semaglutide 2.4mg cardiovascular outcomes — 4yr data9 replies
TRIUMPH program (retatrutide) — Phase 3 trial design and endpoints13 replies
Orforglipron ATTAIN trials — oral non-peptide GLP-1 agonist8 replies
CagriSema (amylin + semaglutide) — REDEFINE Phase 3 results20 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register